PIKFYVE and cancer: Using pre-treatment RNA-sequencing data from tumors obtained from a stage IV ICB-treated pan-cancer cohort (n = 108; Dataset S1) at the University of Michigan (U-M), we found that high pre-treatment PIKFYVE expression was significantly associated with poorer response to ICB (Fig. 4E).